Topics

Clinical Trials About "Teva Present Long Term Data Efficacy Safety Fremanezumab" RSS

16:39 EDT 20th September 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Teva Present Long Term Data Efficacy Safety Fremanezumab" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Teva Present Long Term Data Efficacy Safety Fremanezumab" on BioPortfolio

We have published hundreds of Teva Present Long Term Data Efficacy Safety Fremanezumab news stories on BioPortfolio along with dozens of Teva Present Long Term Data Efficacy Safety Fremanezumab Clinical Trials and PubMed Articles about Teva Present Long Term Data Efficacy Safety Fremanezumab for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Teva Present Long Term Data Efficacy Safety Fremanezumab Companies in our database. You can also find out about relevant Teva Present Long Term Data Efficacy Safety Fremanezumab Drugs and Medications on this site too.

Showing "Teva Present Long Term Data Efficacy Safety Fremanezumab" Clinical Trials 1–25 of 55,000+

Extremely Relevant

Expanded Access Program for Patients With Migraine

This expanded access program is designed to make fremanezumab available to patients with EM or CM who have successfully completed (per protocol) Teva-sponsored Study TV48125-CNS-30051 or TV48125-CNS-30068 ("prior studies") until fremanezumab becomes commercially available in their country.


A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

The primary objective is to evaluate the efficacy of monthly 225 mg sc fremanezumab in adult patients with migraine and major depressive disorder (MDD) The secondary objectives are to evaluate the efficacy of monthly 225 mg sc of fremanezumab in adult patients with migraine and on the reduction of MDD symptoms, responder rates in monthly migraine days, improving quality of life, improving disability, and the safety and tolerability of monthly 225 mg sc and quarterly 675 mg sc ...

A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With Fibromyalgia

The primary objective of the study is to estimate the treatment effect of fremanezumab administered subcutaneously in reducing pain in adult patients with FM. A secondary objective is to evaluate the effect of fremanezumab on other efficacy measures, including pain, quality of life, sleep, fatigue, improvement in health, physical functioning, and mood. Another secondary objective is to evaluate the safety and tolerability of fremanezumab administered subcutaneously in adult pat...


An Efficacy and Safety Study of Fremanezumab in Adults With Migraine

The purpose of this study is to evaluate the efficacy, safety, and tolerability of monthly and quarterly subcutaneous (sc) injections of fremanezumab compared with sc injections of placebo in patients with chronic migraine (CM) or episodic migraine (EM) who have responded inadequately to 2 to 4 classes of prior preventive treatments. Approximately equal numbers of patients from each subgroup (CM and EM) are randomized in blinded-fashion 1:1:1 into one of three treatments for t...

A Study Comparing 1 Subcutaneous Dose Regimen of Fremanezumab Versus Placebo for the Prevention of PPTH

This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of fremanezumab in adult patients aged 18 to 70 years, inclusive, for the prevention of PPTH. Patients will provide written informed consent and during study visits they will use an electronic diary application daily, to report their headache status and other health information. Efficacy and immunogenicity status will be captured periodically an...

Relevant

Long-Term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)

The aim of this long-term study is to investigate the effect of roflumilast (APTA-2217) on the long-term safety in patients with asthma, who completed the 24-week evaluation of study APTA-2217-05. Roflumilast will be administered orally once daily. The present study consists of a 28 weeks treatment period, and is the extension of the 24-week study APTA-2217-05 (registered study). The study will provide further long-term safety and efficacy data of roflumilast.

Long-Term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-08)

The aim of this long-term study is to investigate the effect of roflumilast (APTA-2217) on the long-term safety in patients with chronic obstructive pulmonary disease (COPD) who completed the 24-week evaluation of study APTA-2217-06. Roflumilast will be administered orally once daily. The present study consists of a 28 weeks treatment period, and is an extension of the 24-week study APTA-2217-06 (registered study). The study will provide further long-term safety and efficacy da...

This is a Two-Year Follow-up Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus

This extension study is designed to provide long-term safety and efficacy data beyond 12 months up to Month 36.

Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis

The objective of the clinical study of the medicinal product for medical use: to compare efficacy and safety of the generic drug BCD-063 and Copaxone®-Teva in patients with relapsing-remitting multiple sclerosis. Period of the clinical study of the medicinal product for medical use: from June 10, 2013 to March 23, 2016. Number of patients, involved into the study of the medicinal product for medical use: 158 patients.

PROGRESS-AMS 1.0 Clinical Long Term Follow-Up

The primary objective of this study is to collect long term clinical follow-up data on all patients enrolled in the PROGRESS AMS-1.0 study to assess long term safety of the AMS-1.0

Long-Term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)

The scientific aim of the present extension study is to monitor long-term safety and tolerability of idebenone in patients with DMD. Furthermore, the long-term effect on respiratory, cardiac and motor functions, and skeletal muscle strength/function will be assessed.

Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis

This study will assess the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density, and long term maintenance of health-related quality of life.

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

The primary objective of this trial is to evaluate the long-term safety of BIBF 1120 in terms of incidence and intensity of Adverse Events and changes in safety laboratory parameters. Secondary objectives are the collection of further safety data (vital signs), efficacy data and the determination of pharmacokinetic characteristics during long-term therapy with BIBF 1120.

Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia

The therapeutic advantage of the association of ATRA + Arsenic Trioxide is more favorable and manageable as compared to ATRA + chemotherapy. Nevertheless, at present, there is not enough information on the incidence of long-term side effects. This study, as well as other similar studies conducted around Europe, will focus on following patients treated with this therapy on a long-term basis. Once all studies in Europe will be concluded, all data will be analyzed together.

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

The aim of this international prospective, non-interventional post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer in treatment of patients with haemophilia A under daily-life treatment conditions.

Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America

The aim of this international prospective post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer/FS in treatment of patients with haemophilia A under daily-life treatment conditions.

EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan

The aim of this international prospective post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer/FS in treatment of patients with haemophilia A under daily-life treatment conditions.

This is a 2-Year Follow-up Study to Evaluate the Long-Term Effects in Patients Who Completed the Study CRAD001A2307.

This extension study is designed to provide long-term safety and efficacy data beyond 12 months up to Month 36.

Creon After Pancreatic Surgery

This study will provide efficacy data for Creon 25000 MMS in PS patients as well as long-term safety data. During the long-term treatment with Creon 25000 nutritional parameters will be assessed and correlated with CFA

REQUIP (Ropinirole Hydrochloride)IR Long-Term Phase 4 Study

REQUIP was granted approval for the treatment of Parkinson's Disease on 20 October 2006. REQUIP is expected to be used for a long term in clinical practice. However, no long-term clinical data with REQUIP administered three times daily are currently available from Japanese patients, and the clinical experience with REQUIP at >10mg/day is limited. For this reason, this study was designed as a multicenter open-label uncontrolled study. This study will evaluate the long-term ef...

A Long-term Safety and Efficacy of EnXtra (E-AG-01) in Healthy Adults

The present study has been proposed to investigate the long-term safety and efficacy of EnXtra in healthy adults habituated to caffeine.

Open-Lable, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus

The purpose of this study is to investigate the long-term safety and tolerability and efficacy of neramxane mesylate in the long-term treamtent of subjective tinnitus after a double-blind randomized placebo controlled study

Long-Term Extension Study of PB1046 in PAH Subjects Having Completed Studies PB1046-PT-CL-0004 or PB1046-PT-CL-0005

This is a multi-center, Phase 2 Long-Term Extension Study to assess the safety, tolerability, and efficacy of PB1046 at an optimally titrated dose. This is a Long-Term Extension Study for subjects with pulmonary arterial hypertension (PAH), having participated in double-blind Study PB1046-PT-CL-0004 or open-label Study PB1046-PT-CL-0005. The study will include adult subjects previously diagnosed with symptomatic PAH, who are receiving background clinician-directed therapy for P...

A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.

The purpose of this survey is to identify any concerns regarding the following efficacy and safety-related issues in clinical practice with the new drugs "Fabrazyme for intravenous infusion 5mg" and "Fabrazyme for intravenous infusion 35mg" and to confirm the safety of these products in long-term use in the clinical setting. 1. New adverse drug reactions (ADRs) that cannot be predicted from the Precautions (in particular, clinically significant ADRs) 2. The inc...

Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan

The special use-results surveillance is conducted in patients who have never been treated with Enbrel and in whom its long-term therapy may be instituted in the actual setting of use after marketing with the following objectives:1. To examine the safety of long-term use of Enbrel including the occurrence of malignant tumors.2. To confirm the efficacy of Enbrel in the long-term use.


More From BioPortfolio on "Teva Present Long Term Data Efficacy Safety Fremanezumab"

Quick Search